FOLH1 and prostate cancer: An anti-prostate-specific membrane antigen (PSMA) antibody was fused with the gp3 protein to create an anti-PSMA-M13-SWNT platform that targets prostate cancer cells and can be used for in vivo fluorescence imaging [87].